Filing Overview
Registrant: Jupiter Wellness, Inc. The request metadata identifies BONK, Inc., but the filing is for Jupiter Wellness, Inc. and reports an event dated June 16, 2021, filed June 17, 2021.
The Form 8-K reports a material license agreement, an unregistered equity issuance, and related Regulation FD disclosure. No financial statements or operating-period results are included.
Material Agreement and Transaction
- Jupiter entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) for an exclusive worldwide license to specified patents, know-how, and materials relating to the use of aspartame in treating contact dermatitis.
- The license permits Jupiter to make, use, distribute, sublicense, and sell related products or services.
- The agreement became effective June 16, 2021, and expires upon expiration of the last valid patent claim covered by the agreement.
- Jupiter agreed to issue OMRF $375,000 worth of common stock as an initial payment under an exemption from Securities Act registration, relying on Section 4(2) and/or Regulation D.
- Jupiter must pay OMRF an additional $1,000,000 if annual worldwide net sales of the first licensed product reach $10,000,000.
- The transaction supports research into potential CBD/aspartame treatments for skin conditions, including atopic dermatitis.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, balance-sheet, or other operating-performance metrics. It also does not state the number of shares issued, the per-share valuation used for the $375,000 stock payment, or the resulting ownership dilution.
Outlook, Risks, and Unusual Items
- The license relates to research and potential products; the filing does not provide commercialization timing, regulatory approval status, sales forecasts, or financial guidance.
- The additional $1,000,000 payment is contingent on achieving the stated sales threshold.
- Investors should consider patent validity and remaining patent life, development and regulatory risks, product-market acceptance, and the uncertainty of generating licensed-product sales.
- The issuance of common stock without registration may create dilution for existing shareholders.
- The filing does not describe termination rights, royalty obligations, milestones other than the sales-triggered payment, or other economic terms beyond those summarized above.
Key Facts to Verify
- Confirm that the filing issuer is Jupiter Wellness, Inc., not BONK, Inc.
- Review the complete June 16, 2021 license agreement for royalties, sublicensing terms, termination provisions, indemnities, and additional milestones.
- Verify the number and valuation of common shares issued to OMRF and the associated dilution.
- Confirm patent status, expiration dates, and the scope of the licensed claims.
- Assess the regulatory and clinical pathway for any CBD/aspartame product before relying on the potential commercial opportunity.